ARCA Biopharma (ABIO) said late Thursday that it completed its merger with Oruka Therapeutics following a stockholder approval at a special meeting on Aug. 22.
In addition, the combined company will implement a reverse stock split at a ratio of 1-for-12 shares, the company said.
The combined company will operate under Oruka Therapeutics, with shares to begin trading on a post-reverse split on Nasdaq under the ORKA ticker symbol from Sept. 3.
Price: 2.5500, Change: +0.05, Percent Change: +2.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments